Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Cobenfy (KarXT; xanomeline-trospium) developed by Bristol Myers Squibb|schizophrenia and psychosis related to Alzheimer’s disease. Amid setbacks for emerging schizophrenia treatments, the approval of ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.